Alpha 2.0
Login Register
» Articles » PMID: 35907929

Design of Predictive Model to Optimize the Solubility of Oxaprozin As Nonsteroidal Anti-inflammatory Drug

Overview
Journal Sci Rep
Specialty Science
Date 2022 Jul 30
PMID 35907929
Authors
Sameer Alshehri
Mohammed Alqarni
Nader Ibrahim Namazi
Ibrahim A Naguib
Kumar Venkatesan
Yasser O Mosaad
Mahboubeh Pishnamazi
Amal M Alsubaiyel
Mohammed A S Abourehab
Affiliations
Soon will be listed here.
Abstract

These days, many efforts have been made to increase and develop the solubility and bioavailability of novel therapeutic medicines. One of the most believable approaches is the operation of supercritical carbon dioxide fluid (SC-CO). This operation has been used as a unique method in pharmacology due to the brilliant positive points such as colorless nature, cost-effectives, and environmentally friendly. This research project is aimed to mathematically calculate the solubility of Oxaprozin in SC-CO through artificial intelligence. Oxaprozin is a nonsteroidal anti-inflammatory drug which is useful in arthritis disease to improve swelling and pain. Oxaprozin is a type of BCS class II (Biopharmaceutical Classification) drug with low solubility and bioavailability. Here in order to optimize and improve the solubility of Oxaprozin, three ensemble decision tree-based models including random forest (RF), Extremely random trees (ET), and gradient boosting (GB) are considered. 32 data vectors are used for this modeling, moreover, temperature and pressure as inputs, and drug solubility as output. Using the MSE metric, ET, RF, and GB illustrated error rates of 6.29E-09, 9.71E-09, and 3.78E-11. Then, using the R-squared metric, they demonstrated results including 0.999, 0.984, and 0.999, respectively. GB is selected as the best fitted model with the optimal values including 33.15 (K) for the temperature, 380.4 (bar) for the pressure and 0.001242 (mole fraction) as optimized value for the solubility.

Citing Articles

Correlation of rivaroxaban solubility in mixed solvents for optimization of solubility using machine learning analysis and validation.

Alanazi M, Alanazi J, Alharby T, Huwaimel B Sci Rep. 2025; 15(1):4725.

PMID: 39922955 PMC: 11807219. DOI: 10.1038/s41598-025-89093-y.

Mesalazine solubility in supercritical carbon dioxide with and without cosolvent and modeling.

Sajadian S, Esfandiari N, Rojas A, Hemmati S, Jouyban A, Aguila G Sci Rep. 2025; 15(1):3870.

PMID: 39890916 PMC: 11785961. DOI: 10.1038/s41598-025-86004-z.

Artificial intelligence-driven systems engineering for next-generation plant-derived biopharmaceuticals.

Parthiban S, Vijeesh T, Gayathri T, Shanmugaraj B, Sharma A, Sathishkumar R Front Plant Sci. 2023; 14:1252166.

PMID: 38034587 PMC: 10684705. DOI: 10.3389/fpls.2023.1252166.

Tailored machine learning for evaluating the long-term diabetes risk in older individuals: findings from the Irish Longitudinal Study on Ageing (TILDA).

Xu X, Mingyang X, Yang J, Zheng H, Che Z BMJ Open. 2023; 13(5):e072991.

PMID: 37253496 PMC: 10255035. DOI: 10.1136/bmjopen-2023-072991.

References
1.
Baldelli A, Boraey M, Nobes D, Vehring R . Analysis of the Particle Formation Process of Structured Microparticles. Mol Pharm. 2015; 12(8):2562-73. DOI: 10.1021/mp500758s. View
2.
Kean W . Oxaprozin: kinetic and dynamic profile in the treatment of pain. Curr Med Res Opin. 2004; 20(8):1275-7. DOI: 10.1185/030079904125004420. View
3.
Xue M, Su Y, Li C, Wang S, Yao H . Identification of Potential Type II Diabetes in a Large-Scale Chinese Population Using a Systematic Machine Learning Framework. J Diabetes Res. 2020; 2020:6873891. PMC: 7532405. DOI: 10.1155/2020/6873891. View
4.
Zeng X, Tu X, Liu Y, Fu X, Su Y . Toward better drug discovery with knowledge graph. Curr Opin Struct Biol. 2021; 72:114-126. DOI: 10.1016/j.sbi.2021.09.003. View
5.
Song Y, Lu Y . Decision tree methods: applications for classification and prediction. Shanghai Arch Psychiatry. 2015; 27(2):130-5. PMC: 4466856. DOI: 10.11919/j.issn.1002-0829.215044. View